The efficacy of eribulin mesylate with trastuzumab for locally advanced or metastatic HER2-positive breast cancer treated with prior pertuzumab and/or T-DM1: Results from a phase II, single arm, multicenter study (N-SOG 10 study)

被引：0
|
作者：
Fujii, M. [1 ]
Tsunoda, N. [2 ]
Hattori, M. [3 ]
Murata, T. [4 ]
Akahane, K. [5 ]
Kamei, K. [6 ]
Goto, Y. [7 ]
Amemiya, T. [8 ]
Nishimae, K. [9 ]
Kubota, T. [10 ]
Ito, Y. [11 ]
Kurumiya, Y. [12 ]
Yoshihara, M. [13 ]
Nakanishi, K. [14 ]
Kikumori, T. [14 ]
Ando, M. [15 ]
Nagino, M. [2 ]
机构：
[1] Aichi Hosp, Aichi Canc Ctr, Dept Breast Oncol, Okazaki, Aichi, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol, Nagoya, Aichi, Japan
[3] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[4] Aichi Canc Ctr, Dept Breast Oncol, Okazaki, Aichi, Japan
[5] Japanese Red Cross Nagoya Daini Hosp, Dept Surg, Nagoya, Aichi, Japan
[6] Ogaki Municipal Hosp, Dept Surg, Oogaki, Japan
[7] Japanese Red Cross Nagoya Daiichi Hosp, Dept Surg, Nagoya, Aichi, Japan
[8] Anjo Kosei Hosp, Dept Surg, Anjo, Japan
[9] Shizuoka Prefectural Gen Hosp, Dept Surg, Shizuoka, Japan
[10] Kamiiida Daiichi Gen Hosp, Dept Breast Surg, Nagoya, Aichi, Japan
[11] Chukyo Hosp, Dept Surg, Nagoya, Aichi, Japan
[12] Toyota Kosei Hosp, Dept Surg, Toyota, Japan
[13] Toyohashi Municipal Hosp, Dept Surg, Toyohashi, Aichi, Japan
[14] Nagoya Univ Hosp, Dept Breast & Endocrine Surg, Nagoya, Aichi, Japan
[15] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
101P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
    Martin, M.
    Fumoleau, P.
    Dewar, J. A.
    Albanell, J.
    Limentani, S. A.
    Campone, M.
    Chang, J. C.
    Patre, M.
    Strasak, A.
    de Haas, S. L.
    Xu, J.
    Garcia-Saenz, J. A.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1249 - 1256
  • [2] Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
    Matsui, K.
    Yoshikawa, A.
    Oyama, K.
    Nozaki, Z.
    Tanada, Y.
    Earashi, M.
    Kiyohara, K.
    Nagata, T.
    Fukushima, W.
    Shimizu, T.
    Maeda, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
    Wilks, Sharon
    Puhalla, Shannon
    O'Shaughnessy, Joyce
    Schwartzberg, Lee
    Berrak, Erhan
    Song, James
    Cox, David
    Vandat, Linda
    CLINICAL BREAST CANCER, 2014, 14 (06) : 405 - 412
  • [4] Eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: results from a phase 2, multicenter, single-arm study
    Vandat, L.
    Schwartzberg, L.
    Wilks, S.
    Rege, J.
    Liao, J.
    Cox, D.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2012, 72
  • [5] A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).
    Miller, K.
    Gianni, L.
    Andre, F.
    Dieras, V.
    Mahtani, R. L.
    Harbeck, N.
    Huang, J. E.
    Shih, T.
    Choi, Y.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
    Dan Lu
    Chunze Li
    Matthew Riggs
    Daniel Polhamus
    Jonathan French
    Priya Agarwal
    Shang-Chiung Chen
    Shweta Vadhavkar
    Monika Patre
    Alexander Strasak
    Angelica Quartino
    Jin Yan Jin
    Sandhya Girish
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 175 - 185
  • [7] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
    Lu, Dan
    Li, Chunze
    Riggs, Matthew
    Polhamus, Daniel
    French, Jonathan
    Agarwal, Priya
    Chen, Shang-Chiung
    Vadhavkar, Shweta
    Patre, Monika
    Strasak, Alexander
    Quartino, Angelica
    Jin, Jin Yan
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 175 - 185
  • [8] T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study
    Conte, Benedetta
    Fabi, Alessandra
    Poggio, Francesca
    Blondeaux, Eva
    Dellepiane, Chiara
    D'Alonzo, Alessia
    Buono, Giuseppe
    Arpino, Grazia
    Magri, Valentina
    Naso, Giuseppe
    Presti, Daniele
    Mura, Silvia
    Fontana, Andrea
    Cognetti, Francesco
    Molinelli, Chiara
    Pastorino, Simona
    Bighin, Claudia
    Miglietta, Loredana
    Boccardo, Francesco
    Lambertini, Matteo
    Del Mastro, Lucia
    CLINICAL BREAST CANCER, 2020, 20 (02) : E181 - E187
  • [9] Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab.
    Modi, Shanu
    Elias, Anthony D.
    LoRusso, Patricia
    Samant, Meghna
    Guardino, Ellie
    Althaus, Betsy
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer
    Wilks, S.
    Puhalla, S.
    O'Shaughnessy, J.
    Schwartzberg, L.
    Berrak, E.
    Song, J.
    Rege, J.
    Cox, D.
    Vahdat, L.
    CANCER RESEARCH, 2013, 73
12345